Feng R - Search Results

1

Treatment of multiple myeloma with SDX-308.

Feng R, Lentzsch S. Feng R, et al. Drug News Perspect. 2007 Sep;20(7):431-5. doi: 10.1358/dnp.2007.20.7.1149631. Drug News Perspect. 2007. PMID: 17992265 Free article. Review.

2

SDX-308, a nonsteroidal anti-inflammatory agent, inhibits NF-kappaB activity, resulting in strong inhibition of osteoclast formation/activity and multiple myeloma cell growth.

Feng R, Anderson G, Xiao G, Elliott G, Leoni L, Mapara MY, Roodman GD, Lentzsch S. Feng R, et al. Blood. 2007 Mar 1;109(5):2130-8. doi: 10.1182/blood-2006-07-027458. Epub 2006 Nov 9. Blood. 2007. PMID: 17095620 Free article.

3

The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage.

Feng R, Oton A, Mapara MY, Anderson G, Belani C, Lentzsch S. Feng R, et al. Br J Haematol. 2007 Nov;139(3):385-97. doi: 10.1111/j.1365-2141.2007.06772.x. Br J Haematol. 2007. PMID: 17910628 Free article.

4

Cell-based and cytokine-directed chemical screen to identify potential anti-multiple myeloma agents.

Feng R, Rios JA, Onishi T, Lokshin A, Gorelik E, Lentzsch S. Feng R, et al. Leuk Res. 2010 Jul;34(7):917-24. doi: 10.1016/j.leukres.2009.12.002. Epub 2010 Feb 8. Leuk Res. 2010. PMID: 20116850

5

KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling.

Feng R, Ma H, Hassig CA, Payne JE, Smith ND, Mapara MY, Hager JH, Lentzsch S. Feng R, et al. Mol Cancer Ther. 2008 Jun;7(6):1494-505. doi: 10.1158/1535-7163.MCT-08-0183. Mol Cancer Ther. 2008. PMID: 18566220

6

Targeting the microtubular network as a new antimyeloma strategy.

Feng R, Li S, Lu C, Andreas C, Stolz DB, Mapara MY, Lentzsch S. Feng R, et al. Mol Cancer Ther. 2011 Oct;10(10):1886-96. doi: 10.1158/1535-7163.MCT-11-0234. Epub 2011 Aug 8. Mol Cancer Ther. 2011. PMID: 21825007

7

Targeting cannabinoid receptor-2 pathway by phenylacetylamide suppresses the proliferation of human myeloma cells through mitotic dysregulation and cytoskeleton disruption.

Feng R, Tong Q, Xie Z, Cheng H, Wang L, Lentzsch S, Roodman GD, Xie XQ. Feng R, et al. Mol Carcinog. 2015 Dec;54(12):1796-806. doi: 10.1002/mc.22251. Epub 2015 Jan 16. Mol Carcinog. 2015. PMID: 25640641 Free PMC article.

8

Multiple myeloma-derived MMP-13 mediates osteoclast fusogenesis and osteolytic disease.

Fu J, Li S, Feng R, Ma H, Sabeh F, Roodman GD, Wang J, Robinson S, Guo XE, Lund T, Normolle D, Mapara MY, Weiss SJ, Lentzsch S. Fu J, et al. Among authors: feng r. J Clin Invest. 2016 May 2;126(5):1759-72. doi: 10.1172/JCI80276. Epub 2016 Apr 4. J Clin Invest. 2016. PMID: 27043283 Free PMC article.

9

Blocking the ZZ domain of sequestosome1/p62 suppresses myeloma growth and osteoclast formation in vitro and induces dramatic bone formation in myeloma-bearing bones in vivo.

Teramachi J, Silbermann R, Yang P, Zhao W, Mohammad KS, Guo J, Anderson JL, Zhou D, Feng R, Myint KZ, Maertz N, Beumer JH, Eiseman JL, Windle JJ, Xie XQ, Roodman GD, Kurihara N. Teramachi J, et al. Among authors: feng r. Leukemia. 2016 Feb;30(2):390-8. doi: 10.1038/leu.2015.229. Epub 2015 Aug 19. Leukemia. 2016. PMID: 26286116 Free PMC article.

10

Novel triaryl sulfonamide derivatives as selective cannabinoid receptor 2 inverse agonists and osteoclast inhibitors: discovery, optimization, and biological evaluation.

Yang P, Wang L, Feng R, Almehizia AA, Tong Q, Myint KZ, Ouyang Q, Alqarni MH, Wang L, Xie XQ. Yang P, et al. Among authors: feng r. J Med Chem. 2013 Mar 14;56(5):2045-58. doi: 10.1021/jm3017464. Epub 2013 Mar 1. J Med Chem. 2013. PMID: 23406429 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,187 results

Search Page

Filters